ストックスクリーナーアプリを入手
1.46
5.81%
-0.09
アフターアワーズ：
1.45
-0.01
-0.68%
前日終値:
$1.55
開ける：
$1.51
24時間の取引高:
382.18K
Relative Volume:
1.10
時価総額：
$175.50M
収益：
-
当期純損益:
$-13.73M
株価収益率:
-11.23
EPS:
-0.13
ネットキャッシュフロー:
$-3.92M
1週間 パフォーマンス:
-18.89%
1か月 パフォーマンス:
-13.61%
6か月 パフォーマンス:
-11.52%
1年 パフォーマンス:
+47.50%
1日の値動き範囲:
$1.39
$1.60
1週間の範囲:
$1.30
$1.82
52週間の値動き範囲:
$0.6295
$2.60
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
TLSA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TLSA
Tiziana Life Sciences Ltd
|
1.46 | 186.32M | 0 | -13.73M | -3.92M | -0.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.52 | 115.43B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.79 | 78.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
862.05 | 52.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.10 | 51.68B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
198.46 | 42.80B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-12-22 | 開始されました | B. Riley Securities | Buy |
| 2018-12-17 | 開始されました | Laidlaw | Buy |
Tiziana Life Sciences Ltd (TLSA) 最新ニュース
Small cap wrap: Tiziana Life Sciences, NanoViricides, 1911 Gold, Protalix BioTherapeutics… - Proactive Investors
Tiziana Life Sciences doses first patient in Phase 2 Alzheimer’s clinical trial - Proactive financial news
Tiziana Life Sciences to Ring the Closing Bell at Nasdaq - The Manila Times
Tiziana Life Sciences doses first patient in Phase 2 Alzheimer's clinical trial - marketscreener.com
TLSA Initiates Phase 2 Trial of Intranasal Foralumab for Alzheimer's Patients - GuruFocus
Tiziana Life Sciences doses first patient in mid-stage Alzheimer’s trial - Proactive financial news
New intranasal antibody trial targets neuroinflammation in early Alzheimer’s - Stock Titan
Tiziana Life Sciences CEO purchases 163,400 shares in open market - Investing.com India
TLSA CEO Bolsters Stake with New Share Acquisition - GuruFocus
Tiziana Life Sciences CEO Increases Stake With Share Purchase - marketscreener.com
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer - The Manila Times
Ivor Elrifi Acquires Additional Shares of Tiziana Life Sciences Amidst Ongoing Clinical Development of Foralumab - Quiver Quantitative
Tiziana CEO boosts stake with open-market share purchase - Proactive financial news
Tiziana Life Sciences withdraws proposed public offering due to market conditions - Investing.com
Tiziana Life Sciences Rescinds Proposed Public Offering - Nasdaq
TLSA Cancels Planned Public Offering Amid Market Conditions - GuruFocus
Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering - The Manila Times
Tiziana Life Sciences announces withdrawal of proposed public offering - marketscreener.com
Tiziana Life Sciences withdraws proposed share offering - Proactive financial news
TLSA Begins Enrollment for Phase 2 Alzheimer's Clinical Trial - GuruFocus
Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 4.4%Here's Why - MarketBeat
Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial - Stock Titan
Tiziana Life Sciences to begin patient dosing in Phase 2 Alzheimer’s trial next week - Proactive financial news
Is Tiziana Life Sciences Ltd a good long term investmentLow Beta Stocks & Make Confident Moves With Forecasting Models - earlytimes.in
Tiziana Life Sciences Shares Drop After Company Unveils Plan to Spin Out IL-6 Program - MSN
Will Tiziana Life Sciences Ltd stock deliver shareholder valueInsider Buying & Daily Stock Trend Watchlist - Newser
How Tiziana Life Sciences Ltd stock reacts to job market data2025 Dividend Review & Stepwise Trade Execution Plans - Newser
Is Tiziana Life Sciences Ltd stock near bottom after declineJuly 2025 Selloffs & Precise Swing Trade Alerts - Newser
Will Tiziana Life Sciences Ltd stock attract ESG investorsWeekly Stock Recap & Low Risk Entry Point Guides - Newser
Tiziana Life Sciences Ltd (TLSA) is looking forward to a strong quarter - setenews.com
Is KN Agri Resources Limited Stock a Safe Long Term Investment Data Breakdown - earlytimes.in
Small cap wrap: Tiziana Life Sciences, Gunnison Copper, Blockmate Ventures, Century Lithium… - Proactive financial news
Is Tiziana Life Sciences Ltd stock undervalued vs historical averagesTrade Exit Report & Weekly Stock Breakout Alerts - Newser
Tiziana Life Sciences to Set Up a Publicly Listed Immunology-Focused Spinout Company, Centered on the IL-6 Market - marketscreener.com
Tiziana Life Sciences stock falls after announcing IL-6 asset spinout By Investing.com - Investing.com Nigeria
Tiziana Life Sciences stock falls after announcing IL-6 asset spinout - Investing.com Nigeria
Tiziana Life Sciences plans spinout of IL-6 antibody program - Proactive financial news
Tiziana Life Sciences (TLSA) Plans Spinout to Develop Anti-IL-6 Antibody - GuruFocus
Tiziana Life Sciences Plans to Spin Off IL-6 Antibody Asset Into New Publicly Listed Company - marketscreener.com
Tiziana Life Sciences Plans to Spin Out Asset as Separate Company - marketscreener.com
Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company - The Manila Times
Tiziana Life Sciences (Nasdaq: TLSA) to spin out IL-6 asset into new listed company - Stock Titan
Tiziana Life Sciences Ltd (TLSA) -5.03% in After-hours: What’s Driving the Move? - Stocks Telegraph
Take Profit: Why Tiziana Life Sciences Ltd stock appeals to dividend seekersQuarterly Profit Summary & AI Based Trade Execution Alerts - moha.gov.vn
Ready to Jump After Recent Trade: Tiziana Life Sciences Ltd (TLSA) - Setenews
Tiziana Life Sciences Ltd (TLSA) -5.3% in After-hours: Amid Routine Trading Conditions - Stocks Telegraph
Small cap wrap: Tiziana Life Sciences, Pinnacle Silver & Gold, Rainbow Rare Earths... - Proactive Investors
Phase 2 Trial of Tiziana Life Sciences' Foralumab Gains MyMatch Program Inclusion - GuruFocus
Tiziana Life Sciences’ Phase 2 foralumab trial joins Healey ALS MyMatch Program - Proactive financial news
Tiziana Life Sciences' Foralumab Phase 2 Trial for ALS Accepted into ALS MyMatch Program at Mass General Brigham - Quiver Quantitative
Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program - The Manila Times
Tiziana Life Sciences Ltd (TLSA) 財務データ
収益
当期純利益
現金流量
EPS
0.18%
0.62%
大文字化:
|
ボリューム (24 時間):